ArticleEuropean journal of nuclear medicine and molecular imaging2021
IntraOmmaya compartmental radioimmunotherapy using
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00089245 (Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Article
- Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma.Theranostics · 2026Article
- Late-stage labeling of diverse peptides and proteins with iodine-125.Journal of pharmaceutical analysis · 2025Review
- Do we need dosimetry for the optimization of theranostics in CNS tumors?Neuro-oncology · 2024Review
- Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.Advances in radiation oncology · 2024Review
- Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma.Biomolecules · 2022Article
- Phase 1 study of intraventricularJournal of hematology & oncology · 2022Article
- Synthesis of Radioiodinated Compounds. Classical Approaches and Achievements of Recent Years.International journal of molecular sciences · 2022Review
- Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.Biomolecules · 2022Review
- The current landscape of immunotherapy for pediatric brain tumors.Nature cancer · 2022Review
- Astatine-211 based radionuclide therapy: Current clinical trial landscape.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeRadioimmunotherapy (RIT) delivered through the cerebrospinal fluid (CSF) has been shown to be a safe and promising treatment for leptomeningeal metastases. Pharmacokinetic models for intraOmmaya antiGD2 monoclonal antibody
methodsSerial CSF samples were collected and radioassayed from 61 patients undergoing a total of 177 intraOmmaya administrations of
resultsThe model fit CSF radioactivity data well (mean R = 96.4%). The median immunoreactivity of
conclusionThe 2-compartmental pharmacokinetic model when applied to intraOmmaya CLINICAL
trial registrationClinicalTrials.gov , NCT00089245.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.